logo
Silicon Labs and Wirepas Surpass 10 Million Chipsets, Powering Industrial IoT at Scale

Silicon Labs and Wirepas Surpass 10 Million Chipsets, Powering Industrial IoT at Scale

Yahoo03-06-2025

AUSTIN, Texas and TAMPERE, Finland, June 3, 2025 /PRNewswire/ -- Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless solutions, and Wirepas, a global leader in decentralized IoT connectivity, today announced they have shipped 10 million wireless SoCs running Wirepas' RF mesh connectivity software, primarily in the Indian market with the Silicon Labs sub-GHz FG23 SoC. These chips power some of the world's largest and most demanding industrial mesh networks across sectors including smart electricity metering, emergency lighting, industrial monitoring and building automation.
The two companies have a long history of collaboration enabling robust, ultra-resilient and massively scalable IoT networks that meet the scale, security, and reliability demands of industrial-grade applications. This milestone confirms that their joint solution is not just technically sound, it is market-proven at scale, and ready to support the digital backbone of global infrastructure.
In December 2024, Silicon Labs and Wirepas announced that four million smart electric meters using Wirepas Mesh software had been deployed in India built on the sub-GHz FG13 and FG23 platforms, helping the country meet the goals of its Advanced Metering Initiative. The solution provides reliable, cost-effective connectivity across dense, complex environments, being a critical enabler for India's ambitious grid modernization and electrification goals.
Another standout success is in Norway, where more than one million similarly-equipped smart meters are connected in a single decentralized mesh network, one of the largest of its kind in the world. These types of deployments demonstrate that robust, self-healing mesh connectivity can now support national-scale infrastructure, laying the groundwork for smarter, more efficient, and more sustainable infrastructure powering cities and industries.
Other segments are also gaining momentum, with some, such as the emergency lighting sector, experiencing very high adoption rates.
"Our partnership with Wirepas is built on a shared vision: to enable industrial-grade wireless connectivity at scale," said Ross Sabolcik, Senior Vice President of Product Lines at Silicon Labs. "By combining Silicon Labs' energy-efficient wireless platforms with Wirepas' decentralized mesh stack, we help our customers build massive, secure, and resilient IoT networks faster and more cost-effectively. We're excited to continue driving transformation across industries together."
"This 10-million milestone demonstrates the unmatched scalability and resilience of our joint solution," said Teppo Hemiä, CEO of Wirepas. "With Silicon Labs' hardware and our mesh software, we've enabled massive networks that simply work, even in the most challenging conditions. Our partnership is helping industries solve real problems at the infrastructure level, accelerating the digitalization and electrification of society."
More information
Read more about the collaboration between Silicon Labs and Wirepas to deliver smart meters to India, here and here.
Learn more about how Silicon Labs and Wirepas are collaborating on the 2.4 GHz spectrum, here.
See more features of the FG23 wireless SoC, here.
About Silicon LabsAbout Silicon Labs Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers with the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at www.silabs.com.
About WirepasWirepas is a global leader in IoT connectivity, providing ultra-resilient, infinitely scalable mesh networks for large-scale industrial and commercial deployments. Its technology connects millions of devices worldwide, including the largest network of more than a million smart electricity meters. With proven 99.99% reliability and a team of deep experts guiding projects from planning to maintenance, Wirepas ensures unmatched business continuity. Wirepas is also the main contributor to and first implementor of the first non-cellular 5G standard NR+, purpose-built for massive IoT and using a free global spectrum. Wirepas operates globally across smart tracking, smart building and smart metering sectors. Learn more on www.wirepas.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/silicon-labs-and-wirepas-surpass-10-million-chipsets-powering-industrial-iot-at-scale-302471407.html
SOURCE Silicon Labs

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Applied Optoelectronics Stock Skyrocketed Today
Why Applied Optoelectronics Stock Skyrocketed Today

Yahoo

time5 hours ago

  • Yahoo

Why Applied Optoelectronics Stock Skyrocketed Today

Applied Optoelectronics stock rocketed higher Friday thanks to new financing disclosures from the company. The tech specialist announced that one of its subsidiaries had taken on a new loan that was used to pay a previously existing loan. News of the refinancing move follows an announcement that the company recently made a major product shipment to a hyperscaler customer. 10 stocks we like better than Applied Optoelectronics › Applied Optoelectronics (NASDAQ: AAOI) stock soared higher again in Friday's trading. The tech specialist's share price rose 18.6% in the daily session despite a 0.2% decline for the S&P 500 (SNPINDEX: ^GSPC) and a 0.5% fall for the Nasdaq Composite (NASDAQINDEX: ^IXIC). Applied Optoelectronics' valuation surged today thanks to news that one of the company's subsidiaries had reworked previously existing debt agreements. The stock climbed roughly 39% over the last week of trading. After the market closed on Wednesday, Applied Optoelectronics submitted a filing to the Securities and Exchange Commission (SEC) revealing two significant financing changes for its Global Technology subsidiary. Because the stock market was closed for the Juneteenth federal holiday on Thursday, the investor reaction to the new disclosures was pushed into today's trading. As per the filing with the SEC, Applied Optoelectronics' Global Technology has entered into a one-year credit agreement with China Construction Bank totaling 96.8 million Chinese renminbi -- which works out to roughly US$111.55 million based on the current exchange rate. Applied Optoelectronics said that the funding from the new agreement had been used to pay back other outstanding loans with Shanghai Pudong Development Bank. Despite this week's rally, Applied Optoelectronics stock is still down roughly 36% across the year due to uneven business performance and concerns about the company's financing. On the other hand, the company has recently announced significant shipments for its high-speed data center transceivers for a major data center customer. Along with some indications that the company could see an increase in demand powered by artificial intelligence (AI) initiatives from cloud hyperscaler customers, the recently announced financing moves suggest that the company has a found a near-term solution to some of its financing challenges. Before you buy stock in Applied Optoelectronics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Optoelectronics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Applied Optoelectronics Stock Skyrocketed Today was originally published by The Motley Fool

Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake

Yahoo

time8 hours ago

  • Yahoo

Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company's next-generation cystic fibrosis treatment, Alyftrek. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. RBC Capital remains concerned about the gradual conversion compared to consensus expectations. Consequently, it has warned it could affect the company's operating margins by up to 2%. Nevertheless, the research firm insists that the company's cystic fibrosis franchise remains well-insulated from sector headwinds. However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current valuation in the market. Consequently, its reduced price target reflects lower year Alyftrek conversion rates. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops and commercializes therapies for serious diseases. They are known for their work in cystic fibrosis (CF) and are expanding into other areas like cell and genetic therapies. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating

Yahoo

time8 hours ago

  • Yahoo

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store